Abeona Therapeutics ABEO 深 滬
等待開盤 05-30 09:30:00 美东时间
5.8365
+0.057
+0.98%
華盛通- 最 高5.93
- 今 開5.78
- 成交量 43.48万股
- 最 低 5.78
- 昨 收 5.78
- 總市值 3.33亿
- 52周最高 7.5401
- 市盈率 靜 5.75
- 換手率 0.76%
- 52周最低 4.00
- 委 比 30.77%
- 總股本 5699.51万
- 歷史最高 750.00
- 量 比 0.65
- 振 幅 2.60%
- 歷史最低 2.19
- 每 手 1
- 風險率 0.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
05-28 18:25
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum
Abeona Therapeutics Inc (($ABEO)) has held its Q1 earnings call. Read on for th...
05-20 13:21
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
On Wednesday, Abeona Therapeutics (NASDAQ:ABEO) discussed first-quarter financi...
05-13 21:51
Abeona Therapeutics posts smaller-than-expected Q1 loss per share
Abeona Therapeutics posts smaller-than-expected Q1 loss per share Overview US biopharma's Q1 net product revenue rose quarter-over-quarter as ZEVASKYN adoption increased Q1 loss per share beat analyst expectations Co has $168.3M in cash, cash equivalents and short-term investments as of March 31, 20
05-13 19:40
Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 25 percent decrease over losses of $(0.24) per share from
05-13 19:35
Abeona Q1 FY26 net loss widens to $17.1 million; revenue rises to $8.7 million
Abeona Q1 FY26 net loss widens to $17.1 million; revenue rises to $8.7 million Abeona Therapeutics posted Q1 2026 revenue of USD 8.7 million, up USD 6.3 million from Q4 2025, as net loss widened to USD 17.1 million, or USD 0.30 per share. Selling, general and administrative expense climbed to USD 19
05-13 19:31
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Abeona Therapeutics Activates Children's Hospital Of Philadelphia As Sixth Qualified Treatment Center To Treat ZEVASKYN Gene-Modified Cellular Sheets
Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the Children's Hospital of
05-11 20:34
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
Abeona Therapeutics Inc. has activated the NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center (QTC) for ZEVASKYN, a gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB). This expansion enhances patient access in the Northeast, leveraging the institution’s expertise in genetic medicines and skin disorders. ZEVASKYN is the first autologous cell sheet-based gen...
04-02 12:30
